Advancing Digital Innovation to Improve Equity and Reduce Financial Toxicity in Cancer Care and Research - CancerX
Frontiers Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma
HER2-Low Status Linked to Superior Survival Among TNBC Patients - Cancer Therapy Advisor
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
The HER2-low revolution in breast oncology: steps forward and emerging challenges - Eleonora Nicolò, Luca Boscolo Bielo, Giuseppe Curigliano, Paolo Tarantino, 2023
I advocated for my health. Here's how. – Prevent Cancer Foundation
Frontiers HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
Experienced A Recent Cancer Diagnosis? Here's Some Advice From The Cancer Community.
Treatment of HER2-Low Triple-Negative Breast Cancer
HRD Biomarker Predicts Response to Neoadjuvant Chemotherapy in TNBC
Journal of Clinical Oncology on X: ASCO Guideline Update: Chemo- and Targeted Therapy for Patients With HER2-Negative Metastatic #BreastCancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative #JCO #BCSM